Ontario

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for October 2026

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Taro Pharmaceuticals Inc.	Taro-Doxepin	Silenor	DOXEPIN HCL	3 mg	tablet	02565102
Taro Pharmaceuticals Inc.	Taro-Doxepin	Silenor	DOXEPIN HCL	6 mg	tablet	02565110
Apotex Inc.	Apo-Bilastine	Blexten	BILASTINE	20 mg	tablet	02570521
Biomed Pharma	Bio-Zopiclone	Imovane	ZOPICLONE	5 mg	tablet	02481006
Biomed Pharma	Bio-Zopiclone	Imovane	ZOPICLONE	7.5 mg	tablet	02481014
Apotex Inc.	Apo-Sumatriptan-Naproxen Sodium	Suvexx	SUMATRIPTAN & NAPROXEN SODIUM	85 mg & 500 mg	tablet	02570165

Biomed Pharma	Bio-Zolmitriptan	Zomig	ZOLMITRIPTAN	2.5 mg	tablet	02512831
Marcan Pharmaceuticals Inc.	Cyclophosphamide for Injection USP	Procytox	CYCLOPHOSPHAMIDE	1000 mg/vial	powder for solution (intravenous)	02560216
Marcan Pharmaceuticals Inc.	Cyclophosphamide for Injection USP	Procytox	CYCLOPHOSPHAMIDE	2000 mg/vial	powder for solution (intravenous)	02560224
Apotex Inc.	Apo-Diclofenac Powder	Cambia	DICLOFENAC POTASSIUM	50 mg/ sachet	powder for oral solution	02567768